No association between temozolomide maintenance and survival after first‐line treatment in primary CNS lymphoma

This publication has 9 references indexed in Scilit:

• Evaluation of coverage, generalisability and validity of the U‐CAN lymphoma biobank in Sweden: A comparison with nationwide registers
  British Journal of Haematology, 2024
• Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
  Annals of Oncology, 2024
• Primary central nervous system lymphoma
  Nature Reviews Disease Primers, 2023
• Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers
  American Journal of Hematology, 2023
• Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C
  Neuro-Oncology, 2022
• Primary central nervous system lymphoma in older adults and the rationale for maintenance strategies: a narrative review
  Annals of Lymphoma, 2021
• U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden
  Acta Oncologica, 2017
• Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227
  Journal of Clinical Oncology, 2016
• Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by The Nordic Lymphoma Group
  Haematologica, 2014